July 14, 2025 Kigali, Rwanda and San Francisco, USA

“The recent revelation that nearly 20% of tested chemotherapy drugs failed basic quality standards is more than just alarming—it is a global public health crisis, with devastating consequences, especially for patients in low and middle-income countries (LMICs)…

…This is not just a technical issue. It is a moral one. Every life deserves the dignity of safe and effective treatment. Governments, industry, and global health institutions must act now—not with more rhetoric, but with real accountability and resources.

We cannot wait for the next heartbreaking study to take this seriously. The time to act is now.” -Eric Karikari Boateng, MS

Read the full op-ed here: https://www.newtimes.co.rw/article/28011/opinions/substandard-cancer-drugs-a-global-scandal-and-public-health-emergency-for-lmics

About Bio Usawa, Inc. (BUI)

Bio Usawa has a singular mission: to manufacture and commercialize high-quality, effective and affordable biosimilars for patients in Africa. We are applying our 100+ years of combined experience in the industry in partnership with governments, agencies, educators and health professionals to make transformative biomedicines in Africa, by Africans, for Africans and beyond. 

Click here to learn more about our company's recent successes and download our new White Paper on Regulatory Approaches to Biosimilars in Africa.